The latest erectile dysfunction drug is showing promise of working even faster than those already on the market. Considering it's $3.5 billion market, what's the trade?   Read More

Trading desks idle as light volume continues. It started on November 1st — sell-side desks started seeing a drop in trading volume, and it has continued through the month. What gives?    Read More

VVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so.    Read More

Stocks opened lower on Tuesday, after a sharp rally in the prior session. Where should investors be looking and how should they play the markets? David Spika, VP and investment strategist at WHG Funds and Bill Smead, CEO and CIO of Smead Capital Management shared their outlooks.    Read More

John Paulson’s hedge fund group, the Paulson Funds, had another strong, if not spectacular quarter, according to an investment letter obtained by CNBC.   Read More

The latest overall job loss numbers showed a loss of 190,000 jobs in September and the unemployment rate rose to 10.2%, the highest unemployment rate since April 1983.  The August and September numbers were revised as well.  Here is a breakdown of where the job losses were as well as which sectors were adding jobs.   Read More

I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck.    Read More

Don’t make your move until then, he says.   Read More

Plus, get seven more names to buoy your portfolio when the previously mentioned eight aren’t working.   Read More

Pfizer, or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman.   Read More